Project to Promote the Evaluation of the Cardiovascular Risk in the Clinical Practice and to Evaluate Its Evolution Following the Implementation of a Preventive Multifactorial Strategy Aimed to Reduce the Total Risk Level (SCORE Algorithm), in Subjects Suffering From Metabolic Syndrome and With a Risk Level ≥5% (LesScore)

NCT00821574 Phase 4 COMPLETED

This study will evaluate the efficacy of a multi factorial preventive scheme of action (including fluvastatin and valsartan) to reduce the overall risk level in patients with metabolic syndrome.

Details

Lead sponsor	Novartis
Phase	Phase 4
Status	COMPLETED
Enrolment	144
Start date	2005-07
Completion	2007-03

Conditions

• Hypertension, Dyslypidaemia

Interventions

• Fluvastatin
• Valsartan
• Hydrochlorothiazide

Primary outcomes

• Change in global risk from baseline to 3 and 9 months, as evaluated by the SCORE algorithm — 9 months